Pre-clinical evaluation of cysteamine bitartrate as a therapeutic agent for mitochondrial respiratory chain disease

Cysteamine bitartrate is a US Food and Drug Administration-approved therapy for nephropathic cystinosis also postulated to enhance glutathione biosynthesis. We hypothesized this antioxidant effect may reduce oxidative stress in primary mitochondrial respiratory chain (RC) disease, improving cellular...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Hum Mol Genet
Main Authors: Guha, Sujay, Konkwo, Chigoziri, Lavorato, Manuela, Mathew, Neal D, Peng, Min, Ostrovsky, Julian, Kwon, Young-Joon, Polyak, Erzsebet, Lightfoot, Richard, Seiler, Christoph, Xiao, Rui, Bennett, Michael, Zhang, Zhe, Nakamaru-Ogiso, Eiko, Falk, Marni J
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2019
Assuntos:
General Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6522065/
https://ncbi.nlm.nih.gov/pubmed/30668749
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/hmg/ddz023
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados